Publications

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.

01-11-2014

British journal of cancer

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

26-08-2014

Breast cancer research and treatment

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

01-06-2014

European journal of cancer (Oxford, England : 1990)

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

01-12-2013

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Value of research and value of development in early assessments of new medical technologies.

21-08-2013

International journal of cancer

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

15-08-2013

BMC research notes

Scenario drafting to anticipate future developments in technology assessment.

16-08-2012

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer.

01-02-2012

Breast cancer research and treatment

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.

01-01-2012

BMC cancer

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.

03-11-2011

Annals of surgical oncology

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

01-05-2010

European journal of cancer (Oxford, England : 1990)

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.

01-05-2010

Molecular oncology

Review on early technology assessments of nanotechnologies in oncology.

01-12-2009

International journal of technology assessment in health care

Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.

01-01-2009

Tumori

Early phase Technology Assessment of nanotechnology in oncology.

21-06-2008

The Lancet. Oncology

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

01-12-2007